1. Scrip
  2. >>Therapy Areas

Further Iclaprim Analyses Ahead Of Crucial Months For Motif Bio

 
• By John Davis

A 3 May meeting with the FDA is likely to be crucial for the future commercialization strategy for the biotech’s precision-targeted antibacterial.

Data
The FDA wants to see additional data. • Source: Shutterstock

The under-pressure UK biotech, Motif Bio PLC, has presented more clinical data on its lead Gram-positive targeted investigational antibacterial, iclaprim, as it prepares for a meeting with US regulators on 3 May to discuss the recent turning down of the product’s US marketing submission, announced in February.

In a post hoc evaluation of pooled data from two Phase III studies, REVIVE-1 and REVIVE-2, fixed doses of iclaprim...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.